Recently, Roche announced that its PD-L1 targeted antibody, Tecentriq(atezolizumab), has been approved for marketing in the UK by the Medicines and Healthcare products Regulatory Agency (MHRA).

the combined therapy of KRAS G12D inhibitor MRTX1133 and immune checkpoint inhibitors can cause sustained tumor elimination and significantly improve the survival outcomes in mice.

On August 29, FibroGen announced that the CTGF antibody Pamrevlumab for the treatment of Duchenne Muscular Dystrophy (DMD) in the phase three LELANTOS clinical trial did not achieve its primary NSAA endpoint and crucial secondary endpoints.

REGENXBIO Inc. shared the preliminary interim findings from a single-subject, researcher-led first-in-person study of RGX-181.

A striking 74% of assessable patients showcased a premier response of steady disease.

This inaugural human application (FIH) phase 1 examination, is exploring the efficiency of ISA104

Alpine Immune Sciences, Inc., has revealed the successful launch of the second IgA nephropathy (IgAN) dosage group in RUBY-3, a phase 1b/2a

Genexine,assessing the efficacy and security of eftansomatropin alfa (an exclusive long-acting growth hormone by Genexine, also referred to as GX-H9) in children suffering from growth hormone deficiency.

BenevolentAI has now informed that its initial subjects have been administered in Phase I first-in-human trials of its oral phosphodiesterase 10 (PDE10) inhibitor, BEN-8744.

Sugemalimab is an anti-PD-L1 monoclonal antibody developed by CStone Pharmaceuticals.

Recently, BridgeBio Pharma announced that its investigational treatment, acaracides, achieved its primary endpoint in the phase 3 clinical trial.

On August 29, 2023, Novartis released new long-term data from its ORION-8 Phase 3 clinical trial. The data showed that its twice-yearly RNAi therapy, Leqvio (Inclisiran, Sodium Echociliran), in combination with statins.